By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

aiming for a share of the $150 billion weight-loss market. In addition, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed plans to license an experimental obesity drug from China’s Hansoh ...